Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- obese obesity cells cycle differentiation inhibits inhibitors inhibition adipocytes cancers origin 3T3-L1 model drug screening adipokines endocrinology cell-based assays cell based assay cba
- Product Overview:
Obesity is a growing concern worldwide and has reached epidemic proportions in the United States.{10590} It is a risk factor in many major chronic diseases that afflict our society, including cardiovascular disease, diabetes mellitus, and cancer. In recent years, numerous studies have focused on identifying the mechanism of development of obesity, which is a process of either increasing the number of fat cells (fat cell hyperplasia) or enlargement of fat cells with each cell carrying greater amounts of fat (fat cell hypertrophy), or both.{6620,10590} The ability to regulate the cell cycle and differentiation of adipocytes are key in the development and physiology of obesity and also in the origin of cancer. Understanding of these processes is critical to a rational approach to the treatment of obesity and cancer. Cayman’s Adipogenesis Assay Kit provides the reagents required for studying the induction and inhibition of adipogenesis in the established 3T3-L1 model, using the adipogenesis induction procedure. This kit can also be used to screen drug candidates involved in adipogenesis. The classic Oil Red O staining for lipid droplets is used in this kit as an indicator of the degree of adipogenesis, and can be quantified with a plate reader after the dye is conveniently extracted from the lipid droplet.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.